15 results about "Tauroursodeoxycholic acid" patented technology

The invention provides a lipid nanoparticle based on taurochenodeoxycholic acid modification as well as a preparation method and application thereof. The lipid nanoparticle comprises nucleic acid and a lipid carrier encapsulating the nucleic acid, the lipid carrier is prepared from the following components in percentage by mole: 40 to 65 percent of ionized lipid, 5 to 20 percent of structural phospholipid, 20 to 50 percent of sterol component and 0.5 to 5 percent of PEG (Polyethylene Glycol)-lipid, wherein the sterol component comprises cholesterol and taurochenodeoxycholic acid. By replacing cholesterol with taurochenodeoxycholic acid, the membrane order degree and fluidity of the lipid carrier are effectively adjusted, and the targeted delivery and endosome release efficiency of LNP to liver cells is remarkably improved, so that an LNP delivery system can obtain a more remarkable and lasting Lp (a) reduction effect under the same or lower dosage; by optimizing the LNP formula, it is ensured that the LNP preparation has higher controllability and reliability in the production and storage process.

The invention discloses application of the ratio of phosphatidylserine to taurocholic acid. Research finds that compared with assisted reproduction crowds capable of obtaining available embryos after embryo culture, the concentration of phosphatidylserine in follicular fluid of assisted reproduction crowds without available embryos after embryo culture is remarkably reduced, which prompts that phosphatidylserine can be used as a marker for predicting developmental potential of assisted reproduction embryos; the prediction module is used for predicting whether available embryos can be obtained or not in advance in an egg taking stage of assisted reproduction; and the ROC curve verifies that the AUC of the PS (21: 220: 4) is 0.741, and the AUC of the ratio of the PS (21: 220: 4) to the taurocholic acid is 0.784, so that the accuracy and the sensitivity are higher when the ratio of the PS (21: 220: 4) to the taurocholic acid is used as the marker to predict whether available embryos exist or not.

The application provides a traditional Chinese medicine composition for clearing vision and removing nebula and application thereof, and includes bear bile powder and borneol with a mass ratio of 1-5:1; the bear bile powder includes tauroursodeoxycholic acid and tauroursodeoxycholic acid arginine salt with a molar ratio of 0.4-0.9:0.1-0.6. The application converts tauroursodeoxycholic acid in bear bile powder into tauroursodeoxycholic acid arginine salt, so that the molar ratio of tauroursodeoxycholic acid and tauroursodeoxycholic acid arginine salt in bear bile powder is 0.4-0.9:0.1-0.6, and the bear bile powder is compounded with borneol to treat cataract. Experimental results show that when the molar ratio of tauroursodeoxycholic acid and tauroursodeoxycholic acid arginine salt in bear bile powder is 0.4-0.9:0.1-0.6, the effect of the bear bile powder compounded with borneol in treating cataract is significantly better than that of bear bile powder containing only tauroursodeoxycholic acid or bear bile powder containing only tauroursodeoxycholic acid arginine salt, for example, there is a significant difference in slowing down the degree and thickness of lens turbidity.

The application discloses a preparation method of tauroursodeoxycholic acid capsules and belongs to the technical field of capsule preparation. The tauroursodeoxyxycholic acid capsules are prepared by using a high-frequency wave vibration device which is precisely driven by a servo motor, and the high-frequency wave vibration device is internally provided with first and second moving blocks which are distributed at intervals and drive a flexible elastic plate to wave and turn over, and a plurality of contact assemblies are uniformly arranged on the elastic plate. In the process of spraying and wetting, particles continuously roll and disperse, water can be rapidly and uniformly distributed on the surfaces of all particles, and the water absorption block can automatically supplement water for dry particles, and will not absorb water from wet particles, so that local over-wetting or over-drying of the particles is effectively avoided. The tauroursodeoxyxycholic acid capsules not only remarkably improve the uniformity of the surface micro-wetting of the particles, and create ideal conditions for efficient coating of the subsequent flow aid, but also combine the high-efficiency airflow disturbance of the fluidized bed mixer, so that the flow aid such as colloidal silicon dioxide is uniformly covered on the surface of the particles, the stickiness of the active ingredient tauroursodeoxycholic acid is reduced, and the flowability of the particles and the consistency of the capsule loading are improved.

The present application relates to the technical field of diagnostic markers and diagnostic methods for intrahepatic cholestasis of pregnancy (ICP), and in particular to a combination of diagnostic or condition monitoring markers for intrahepatic cholestasis of pregnancy and application thereof. The biomarkers include diagnostic markers for diagnosis and screening, and condition monitoring markers for follow-up; the diagnostic markers include a diagnostic combination marker composed of tauroursodeoxycholic acid and glycochenodeoxycholic acid, and taurohyocholic acid; and the condition monitoring markers include glycochenodeoxycholic acid, glycolcholic acid, and taurohyocholic acid. The technical solution solves the technical problem of the prior art that there is a lack of sensitive and specific diagnostic markers for intrahepatic cholestasis of pregnancy, and has important significance for early diagnosis, auxiliary clinical diagnosis and treatment, and improvement of population quality, and provides a new strategy for the difficult diagnosis and treatment of ICP.

The invention provides a chicken bile extract taurochenodeoxycholic acid as well as an extraction and separation process and application thereof, solves the technical problems of interference of chicken gallbladder protein and fat and poor water solubility of TCDCA, greatly improves the separation purity, is suitable for industrial production, and has a wide application prospect. The taurochenodeoxycholic acid with relatively high purity is separated from the taurochenodeoxycholic acid and is used for reducing and lowering the stress degree of the ducks.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and polyinosinic acid combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment by regulating and controlling the antigen presentation function of cDC1, and the treatment effect of polyinosinic-cytidylic acid is improved. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and polyinosinic-cytidylic acid can better inhibit tumor growth, can effectively promote CD8 + T cell infiltration in tumors, has more cDC1 infiltration in tumor tissues, shows a stronger inhibition effect on tumors, and can be used for preparing drugs for treating tumors. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, alpha-type enzyme, lactic dehydrogenase, beta-type enzyme and glucose dehydrogenase are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multipath enzymatic reaction, and the method has a relatively high application value.

The present application relates to the field of animal reproduction technology, and in particular to a sperm protection agent for improving sperm preservation quality and embryo development potential and application thereof, wherein the effective components of the sperm protection agent are selected from any one or several of acetyl carnitine, glycerophosphocholine, tauroursodeoxycholic acid, glutamic acid, sunflower acylcarnitine, pyridoxal phosphate and glyco ursodeoxycholic acid. Based on the regulation of the OR4C13-G13 / Golf signal axis related to sperm capacitation of the effective components, sperm viability can be maintained during preservation, premature capacitation can be inhibited, and the fertilization rate and embryo development potential can be improved. The present application is suitable for the normal temperature preservation of pig semen and can be extended to other mammalian or human assisted reproduction fields.

The invention relates to the technical field of biology, and particularly discloses a biomarker combination for digestive tract inflammation and application thereof.The biomarker combination comprises the content of taurocholic acid sodium TLCA and the relative expression quantity of baiB, baiE, baiCD and baiG genes in a bai gene family, host metabolite (TLCA) is combined with the expression level of a flora functional gene (bai gene), and the content of the TLCA is increased; a brand-new and efficient biomarker combination is constructed, and the combination is high in intestinal inflammation judgment accuracy and is remarkably superior to a traditional method depending on a single index or a macroscopic flora structure, and the probability of false positive and false negative is effectively reduced.

The invention belongs to the technical field of biology, and particularly relates to an NAD (H) dependent type 3 alpha-hydroxysteroid dehydrogenase mutant E139T, the amino acid sequence of the mutant E139T is shown as SEQ ID NO: 1, and the mutant E139T is obtained by changing the 139th amino acid of wild type 3 alpha-hydroxysteroid dehydrogenase of which the amino acid sequence is SEQ ID NO: 2 into Thr from Glu. The DNA coding sequence of the gene is as shown in SEQ ID NO: 3. The mutant E139T can catalyze oxidation of alpha hydroxyl at C3 site of taurochenodeoxycholic acid (TCDCA) and tauroursodeoxycholic acid (TUDCA), and the activity of the mutant E139T is 1.12 times and 1.38 times that of wild type 3 alpha-hydroxysteroid dehydrogenase. The application prospect in clinical examination of the total bile acid content is huge.

This invention relates to the field of artificial bear bile powder preparation technology, specifically to a novel 7α-hydroxysteroid dehydrogenase gene R-α-1 and its application in the production and conversion of bear bile powder. This method isolates a novel gene catalyzing asymmetric carbonyl reduction reactions from the feces of Sichuan brown bears. This gene encodes a 7α-hydroxysteroid dehydrogenase, which catalyzes the formation of the intermediate tauroursodeoxycholic acid from tauroursodeoxycholic acid, which is further catalyzed by a 7β-hydroxysteroid dehydrogenase to produce tauroursodeoxycholic acid, the main component of bear bile powder. The nucleotide sequence of this gene is shown in SEQ ID NO.1, and its encoded amino acid sequence is shown in SEQ ID NO.2. This technical solution can solve the technical problem that existing types of 7α-hydroxysteroid dehydrogenases cannot meet the needs of large-scale production due to unsatisfactory enzyme activity and thermostability, and has ideal prospects for widespread application.

The invention relates to the technical field of biology, and discloses an application of bear gall powder in preparation of a medicine for treating acute lung injury, the effective components of the medicine comprise Ursodeoxycholic acid, Tauroursodeoxycholic acid, Chenodeoxycholic acid, Deoxycholic acid, 3-Ketocholic acid and the like, and the effective components of the medicine comprise the Ursodeoxycholic acid, the Tauroursodeoxycholic acid, the Chenodeoxycholic acid, the Deoxycholic acid, the 3-Ketocholic acid and the like. During application, at the cellular level, the concentration of the bear gall powder is 6.25-12.5 mu g / mL; at the animal level, the concentration of the bear gall powder is 30-120mg / kg. According to the application of the bear gall powder in preparation of the medicine for treating the acute lung injury, the bear gall powder acts on Keap-1 / Nrf-2 / HO-1 and NF-kappa B signal channels to improve pathological changes of lung tissues and inhibit inflammatory response and oxidative injury, so that ALI is treated, and an earlier-stage experimental basis is provided for subsequent application of the bear gall powder in treatment of lung diseases.

The invention belongs to the technical field of biology, and particularly relates to an NAD (H) dependent type 3 alpha-hydroxysteroid dehydrogenase mutant E139S, the amino acid sequence of the mutant E139S is shown as SEQ ID NO: 1, and the mutant E139S is obtained by changing the 139th amino acid of wild type 3 alpha-hydroxysteroid dehydrogenase of which the amino acid sequence is SEQ ID NO: 2 into Ser from Glu. The DNA coding sequence of the gene is as shown in SEQ ID NO: 3. The mutant E139S can catalyze oxidation of alpha hydroxyl at C3 site of taurochenodeoxycholic acid (TCDCA) and tauroursodeoxycholic acid (TUDCA), and the activity of the mutant E139S is 1.26 times and 1.73 times that of wild type 3 alpha-hydroxysteroid dehydrogenase. The application prospect in clinical examination of the total bile acid content is huge.

The invention discloses a method for preparing a product with a controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid by using three enzymes, the product with the controllable ratio of tauroursodeoxycholic acid to taurochenodeoxycholic acid and application of the method, and belongs to the technical field of biology. According to the method, the immobilized enzymes of the alpha-type enzyme, the lactic dehydrogenase and the beta-type enzyme are adopted to convert a reaction substrate containing taurochenodeoxycholic acid into a product with a controllable ratio of TUDCA to TCDCA through a multi-path enzymatic reaction, and the method has a relatively high application value.